Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul 23:11:1448152.
doi: 10.3389/fmed.2024.1448152. eCollection 2024.

Editorial: Mass spectrometry-based proteomics in drug discovery and development

Martin Pejchinovski  1 , Pedro Magalhães  2 , Jochen Metzger  3
Affiliations
Editorial

Editorial: Mass spectrometry-based proteomics in drug discovery and development

Martin Pejchinovski et al. Front Med (Lausanne). .
No abstract available

Keywords: biomarker; clinical application; drug development; mass spectrometry; proteomics.

PubMed Disclaimer

Conflict of interest statement

MP was employed by Thermo Fisher Scientific. JM was employed by TÜV SÜD Product Service GmbH. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Mass spectrometry-based proteomics in drug discovery and development

References

    1. Duarte TT, Spencer CT. Personalized proteomics: the future of precision medicine. Proteomes. (2016) 4:29. 10.3390/proteomes4040029 - DOI - PMC - PubMed
    1. Hendricks NG, Bhosale SD, Keoseyan AJ, Ortiz J, Stotland A, Seyedmohammad S, et al. . An inflection point in high-throughput proteomics with Orbitrap Astral: analysis of biofluids, cells, and tissues. bioRxiv [Preprint]. (2024). 10.1101/2024.04.26.591396 - DOI - PMC - PubMed
    1. Belczacka I, Pejchinovski M, Krochmal M, Magalhães P, Frantzi M, Mullen W, et al. . Urinary glycopeptide analysis for the investigation of novel biomarkers. Proteomics Clin Appl. (2019) 13:e1800111. 10.1002/prca.201800111 - DOI - PubMed
    1. Frantzi M, Latosinska A, Mischak H. Proteomics in drug development: the dawn of a new era? Proteomics Clin Appl. (2019) 13:e1800087. 10.1002/prca.201800087 - DOI - PubMed
    1. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, et al. . Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med. (2013) 11:220. 10.1186/1741-7015-11-220 - DOI - PMC - PubMed

Publication types

LinkOut - more resources